Streetbeat News

LXRX

Lexicon Pharmaceuticals, Inc.

https://www.lexpharma.com

Industry

Biotechnology

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Open

1.30

Mkt cap

459M

Volume

2.9M

High

1.32

P/E Ratio

-1.63

52-wk high

3.73

Low

1.20

Div yield

N/A

52-wk low

0.92

Several stocks are experiencing significant pre-market movements. Immunic, Inc. (NASDAQ:IMUX) shares gained 13.2% after positive interim data from a Phase 2 trial. SuperCom Ltd. (NASDAQ:SPCB), Tempest Therapeutics, Inc. (NASDAQ:TPST), Mobilicom Limited (NASDAQ:MOB), SMX (Security Matters) Public Limited Company (NASDAQ:SMX), ContraFect Corporation (NASDAQ:CFRX), and ParaZero Technologies Ltd. (NASDAQ:PRZO) also saw pre-market gains. On the other hand, Borqs Technologies, Inc. (NASDAQ:BRQS), Phoenix Motor Inc. (NASDAQ:PEV), Atreca, Inc. (NASDAQ:BCEL), RVL Pharmaceuticals plc (NASDAQ:RVLP), Molekule Group, Inc. (NASDAQ:MKUL), Windtree Therapeutics, Inc. (NASDAQ:WINT), Applied UV, Inc. (NASDAQ:AUVI), Vascular Biogenics Ltd. (NASDAQ:VBLT), Maison Solutions Inc. (NASDAQ:MSS), and Future FinTech Group Inc. (NASDAQ:FTFT) experienced pre-market losses.

Portfolio Pulse from Lisa Levin

October 10, 2023 | 12:20 pm

Several healthcare stocks experienced significant movement in Monday's after-market session. Immunic, Akero Therapeutics, Lexicon Pharmaceuticals, Aclarion, Geovax Labs, and 89bio saw their shares increase, while Ventyx Biosciences, iSpecimen, Hyperfine, Scinai Immunotherapeutics, RVL Pharmaceuticals, and Vaccinex experienced a decline in their stock prices.

Portfolio Pulse from Benzinga Insights

October 09, 2023 | 9:31 pm

Lexicon Pharmaceuticals' heart failure treatment, INPEFA, has been approved by the FDA and will be listed as a preferred product on Express Scripts' Medicare national formularies from November 1, 2023. This will provide access to INPEFA for Express Scripts Medicare patients who meet the parameters of INPEFA's FDA-approved indication.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2023 | 8:03 pm

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) will present a new analysis of clinical trial data for INPEFA® (sotagliflozin) at the Heart Failure Society of America (HFSA) Annual Scientific Meeting. The drug, recently approved by the FDA for the treatment of heart failure, was studied in two Phase 3 cardiovascular outcomes studies. The presentation will focus on the drug's ability to reduce the risk of cardiovascular events in patients with left ventricular hypertrophy without hypertension.

Portfolio Pulse from Benzinga Newsdesk

September 28, 2023 | 1:11 pm

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) announced several upcoming data presentations related to heart failure, type 1 diabetes, and diabetic peripheral neuropathic pain at the 59th Annual Meeting of EASD. The presentations will include results from studies on INPEFA® (sotagliflozin), recently approved by FDA for heart failure treatment, and LX9211, an investigational, non-opioid treatment for diabetic peripheral neuropathic pain. LX9211 has received Fast Track designation from the FDA and is expected to advance into late-stage development before the end of 2023.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 1:22 pm

Several US stocks recorded losses on Monday, including Scilex Holding Company, Canopy Growth Corporation, Nuvalent, DocGo, GigaCloud Technology, Eos Energy Enterprises, Unity Software, FingerMotion, Rumble, Butterfly Network, Couchbase, Caribou Biosciences, Moderna, Lexicon Pharmaceuticals, Wayfair, The Gap, Viking Therapeutics, AMC Entertainment Holdings, Tellurian, MINISO Group Holding, and Arm Holdings.

Portfolio Pulse from Lisa Levin

September 18, 2023 | 3:08 pm

Lexicon Pharmaceuticals has announced a series of presentations related to LX9211, its investigational drug for the treatment of diabetic peripheral neuropathic pain.

Portfolio Pulse from Benzinga Newsdesk

September 07, 2023 | 1:00 pm

Lexicon Pharmaceuticals is set to present analyses of its INPEFA clinical study results and changing patterns of heart failure diagnoses at the European Society of Cardiology Congress 2023.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2023 | 1:06 pm

A post-hoc analysis of SOLOIST-WHF clinical data published in the Journal of the American College of Cardiology shows that Sotagliflozin significantly reduces the risk of hospital readmissions for heart failure. The risk reductions are approximately 50% for heart failure readmissions and for the composite of CV death and heart failure readmissions at 30- and 90-days following hospital discharge.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 1:05 pm

Insiders at Lexicon Pharmaceuticals, Gaia, and Superior Industries International have recently acquired shares in their respective companies. Lexicon Pharmaceuticals and Gaia reported wider-than-expected Q2 losses, while Superior Industries posted downbeat quarterly sales.

Portfolio Pulse from Lisa Levin

August 08, 2023 | 12:50 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.